Follicular cystitis (FC) is a chronic form of cystitis with uncertain etiology, characterized by the presence of lymphoid follicles in the bladder mucosa as a result of chronic irritation. This can be caused by various factors such as prolonged catheterization, lithiasis, recurrent urinary tract infections or neoplastic bladder pathology. Although it is a rare pathology, it is mainly seen in women over 50 years of age and manifests with nonspecific urinary symptoms such as dysuria, pollakiuria, haematuria and suprapubic pain. We describe a case of a 12-year-old boy with dysuria, haematuria and hypogastric pain. Despite the absence of a history of lithiasis or trauma, and no bacteria found in urinalysis, erythrocytes and leukocytes were found, along with reactivated and degenerated urothelial cells accompanied by heterogeneous-sized cells with a high nucleus/cytoplasm ratio. Ultrasonography showed no abnormalities, but cystoscopy revealed irregularities in the trigone of the bladder and biopsy confirmed the presence of lymphoid follicles, characteristic of FC. This case underscores the relevance of considering FC in patients with persistent bladder irritation and recurrent haematuria. Cystoscopy and histologic evaluation are crucial for an accurate diagnosis, although the role of the clinical laboratory is limited, an experienced specialist can facilitate a proper diagnosis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11726326 | PMC |
EJIFCC
December 2024
Department of Clinical Analysis, Hospital Can Misses, Eivissa, Spain.
Follicular cystitis (FC) is a chronic form of cystitis with uncertain etiology, characterized by the presence of lymphoid follicles in the bladder mucosa as a result of chronic irritation. This can be caused by various factors such as prolonged catheterization, lithiasis, recurrent urinary tract infections or neoplastic bladder pathology. Although it is a rare pathology, it is mainly seen in women over 50 years of age and manifests with nonspecific urinary symptoms such as dysuria, pollakiuria, haematuria and suprapubic pain.
View Article and Find Full Text PDFInt J Surg Case Rep
January 2025
Urology A Department, University Hospital IBN SINA, Morocco.
Introduction And Importance: Follicular cystitis (FC) is a rare inflammatory disorder of the bladder that predominantly affects women. The exact cause of FC remains largely unknown, although it has been associated with inflammatory processes and bacterial infections, particularly following urinary tract infections. Regarding orphan diseases, like follicular cystitis, where large-scale trials seem virtually impossible, case reports find their place and guide the scientific community to find the best course of action.
View Article and Find Full Text PDFExpert Opin Drug Saf
October 2024
Department of Urology, Hengyang Central Hospital, Affiliated Hengyang Hospital of Hunan Normal University, Hengyang, Hunan, China.
Background: Leuprorelin, a gonadotropin-releasing hormone agonist, is widely used to treat hormone-related disorders. This study aims to explore and analyze the safety profile of leuprorelin by examining adverse event reports from the FDA Adverse Event Reporting System (FAERS) database.
Methods: This study conducted a retrospective pharmacovigilance analysis using FAERS data from Q1 2004 to Q1 2024.
Beijing Da Xue Xue Bao Yi Xue Ban
October 2024
Department of Urology, Peking University People's Hospital; The Institute of Applied Lithotripsy Technology, Peking University, Beijing 100044, China.
Heliyon
August 2024
Department of Orthopedics, The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Purpose: This research focused on meticulously tracking and identifying adverse reactions associated with leuprorelin, a drug prescribed for conditions such as prostate cancer, endometriosis, uterine fibroids, and early-onset puberty. The main objective was to enhance patient safety and offer informed guidance on the appropriate use of this treatment.
Methods: From the first quarter of 2004 to the fourth quarter of 2023, a comprehensive analysis was conducted on a significant number of adverse event reports (AERs) from the FDA Adverse Event Reporting System (FAERS) database.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!